Berenberg Bank Reiterates GlobalData (GLDAF) Buy Recommendation

Berenberg Bank reiterated a Buy on GlobalData (OTCPK:GLDAF) on Nov. 28, 2025, while the average one-year analyst price target of $3.24 implies a modest 1.73% downside to the last close of $3.30 (targets range $2.42–$4.06). Company projections show annual revenue of $291M (down 3.63%) and projected non-GAAP EPS of $0.54. Institutional interest ticked up modestly: 22 funds report positions (one additional owner), total institutional shares rose 8.97% to 10.93M, and average fund portfolio weight is 0.20% (up 29.64%).

Analysis

Market structure: The Berenberg reiteration with a $3.24 average PT (vs $3.30 close) signals neutral near-term investor conviction but rising institutional ownership (+8.97% to 10.93M shares) benefits boutique data vendors with visible recurring revenue. Winners are scale incumbents (SPGI, RElX, FACT) that can use M&A to consolidate; smaller peers like GLDAF face pricing pressure and client churn risk if macro slows subscription spend. Cross-asset impact is muted — negligible bond or commodity effect; FX sensitivity exists if revenue mix is GBP/EUR vs USD, and limited options liquidity on OTC-listed GLDAF raises execution risk for derivatives trades.

Risk assessment: Tail risks include a material client renewal shock (>-10% ARR decline in a quarter), regulatory data-privacy sanctions in EMEA, or a failed integration if management pursues M&A; these could cut EPS >20% year-over-year. Immediate (days) — expect low volatility; short-term (3–6 months) — revenue guidance misses could compress price 15–30%; long-term (12–36 months) — consolidation or strategic sale could re-rate valuations. Hidden dependencies: FX translation and a handful of large accounts likely concentrate >20% of revenue, raising churn sensitivity. Key catalysts: quarterly renewals, FY guidance, and any M&A chatter within 30–90 days.

Trade implications: Given limited upside in consensus PT distribution ($2.42–$4.06) and OTC liquidity, size exposure conservatively: tactical long only at <$3.00 with strict stops, or construct relative trades vs large-cap data names. Options on GLDAF are likely illiquid — prefer options on SPGI/RELX for sector exposure (buy 9–12 month call spreads) while using a small equity position in GLDAF as a volatility/alpha play. Time entries to post-earnings windows or after a 10%+ institutional accumulation signal.

Contrarian angles: Consensus underweights acquisition probability — peers historically acquired at 1.5–3x revenue; with GLDAF projected revenue ~$291M, even a mid-range takeout would imply significant upside versus current market cap if strategic buyer interest materializes. The market may be over-penalizing growth risk while ignoring recurring revenue quality — if renewal rates hold within 90–95%, downside is limited to single-digit under current PTs. Unintended consequence: increased ETF/small-cap passive flows could bid small-cap data names mechanically without fundamental improvement, creating short-term squeezes; watch 13F changes for momentum signals.

Key Decisions for Investors

• Establish a tactical long position in GLDAF (OTCPK:GLDAF) sized 0.25–0.75% of portfolio if the share price trades <= $3.00; set hard stop-loss at $2.50 and target exit at $4.00 within 6–12 months, increase to 1.5% only if institutional holdings rise another +10% in next quarter.
• Execute a relative-value pair: long SPGI (S&P Global) equal-weighted 0.5% of portfolio vs short GLDAF 0.5% to capture scale/market-share premium over 6–12 months; rebalance if GLDAF outperforms by >15% or SPGI underperforms by >10%.
• Avoid buying options on GLDAF due to OTC illiquidity; instead purchase 9–12 month call spreads on SPGI or RELX (buy 5–10% OTM, sell 15–20% OTM) sized 0.5% to express sector upside with defined risk.
• Monitor three metrics in the next 30–90 days and act: quarterly renewal rate (threshold <90% = reduce GLDAF to zero), institutional ownership change (>=+10% = add up to target), and any M&A rumors or regulatory notices (confirm before increasing exposure).